Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy

University of Maryland Greenebaum Cancer Center, Baltimore, MD, United States.
Leukemia research (Impact Factor: 2.36). 12/2012; 37(3). DOI: 10.1016/j.leukres.2012.11.001
Source: PubMed

ABSTRACT Given evidence for the role of Src family kinases, especially Lyn kinase, in myeloblast proliferation and the in vitro inhibitory activity of dasatinib on Src and Lyn, we conducted a phase II study to assess overall response to 100mg/day dasatinib in patients with higher-risk myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia arising from MDS and who had failed prior treatment with azanucleoside analogs. Among 18 patients treated, 3 responded, 4 had stable disease, and 10 experienced disease progression. Toxicities were limited and consistent with previous reports. Dasatinib appears to be safe but with limited efficacy.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Outcome in patients with myelodysplastic syndrome (MDS) after azanucleosides failure is poor with unmet need for active novel agents. Preclinical data have suggested that erlotinib has in vivo and in vitro off EGFR-target activity in MDS. We conducted a phase II study with single-agent erlotinib 150 mg/day orally in MDS patients following azanucleoside failure. All intermediate-2 or high-risk MDS patients by International Prognostic Scoring System and only those low/intermediate-1 patients with transfusion-dependent anemia or platelet counts <50x109/L or a significant clinical hemorrhage requiring platelet transfusion or ANC <1x109/L were eligible, with most of our patients being high risk. In 35 eligible patients, overall best response was 14% (3 patients having marrow complete response and 2 hematological improvement). Four deaths occurred on study (sepsis, intracranial hemorrhage, sudden death, and AML). The most common observed grade 3/4 toxicities according to CTCAE v3 were diarrhea (17.1%), rash (17.1%), and infection (11.6%), with fatigue, thrombocytopenia, and anorexia at 5.7% each. Median overall survival was 6.8 months (95% CI 4.9-13.2), and leukemia-free survival was 5 months (95% CI 3.4-7.3). Erlotinib was generally well tolerated, with modest single-agent activity. Given these results and preclinical data suggesting synergistic effect with azanucleosides, the combination should be further explored.
    American Journal of Hematology 04/2014; 89(8). DOI:10.1002/ajh.23749 · 3.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Based on the thieno[2,3-d]pyrimidine scaffold, a series of new 4-amino-6-aryl thienopyrimidines have been prepared and evaluated as EGFR tyrosine kinase inhibitors. The in vitro activity was found to depend strongly on the substitution pattern in the 6-aryl ring, the stereochemistry, and the basicity at the secondary 4-amino group. A stepwise optimization by combination of active fragments led to the discovery of three structures with EGFR IC50 < 1 nM. The most potent drug candidate had an IC50 of 0.3 nM towards EGFR and its mutants L858R and L861Q. Studies using human cancer cell lines and an EGFR-L858R reporter cell system revealed good cellular potency, verifying the identified thienopyrimidines as promising lead structures.
    European Journal of Medicinal Chemistry 03/2014; 75:354–374. DOI:10.1016/j.ejmech.2014.01.042 · 3.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract The Src family protein tyrosine kinases (SFKs) are non-receptor intracellular kinases that have important roles in both hematopoiesis and leukemogenesis. The derangement of their expression or activation has been demonstrated to contribute to hematological malignancies. This review first examines the mechanisms of SFK overexpression and hyperactivation, emphasizing the dysregulation of the upstream modulators. Subsequently, the role of SFK upregulation in the initiation, progression and therapy resistance of many hematological malignancies will also be analysed. The presented evidence will endeavour to highlight the influence of SFK upregulation on an extensive number of hematological malignancies and the need to consider them as candidates in targeted anticancer therapy.
    Leukemia and Lymphoma 06/2014; 56(3):1-20. DOI:10.3109/10428194.2014.907897 · 2.61 Impact Factor